Category Archives: Mesenchymal Stem Cells

Silviu Itescu. Shares in stem cell group Mesoblast surged to two-month highs on its decision on Friday to outlay up to $US100 million to buy a suite of patents in the US that hold the potential to deliver revenues sooner than expected. In a deal with US-based Osiris Therapeutic for an initial $US20 million in cash, along with further future payments, Mesoblast is to gain access to two products in their final stage of clinical trials which already hold approvals for sale in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years. ''These are substantially derisked,'' Mesoblast chief executive Silviu Itescu said of the two advanced products, an agent for treating some Crohn's disease cases along with a treatment for bone marrow cases resulting from stem cell transplants. Mesoblast shares closed up 4.7 per cent on Friday at $5.74. Advertisement Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells that can help body tissue heal large wounds and repair cartilage and muscle tissue. Osiris has been producing these stem cells in the US since 1999, and also has a joint venture in Japan. … Continue reading →

Shares in stem cells group Mesoblast have surged back to their highest level in two months on news it is to spend up to $100 million buying a suite of patents in the US which have the potential to deliver revenues sooner than expected. Earlier today, it disclosed details of the purchase of a clutch of assets from US-based Osiris Therapeutic for an initial $US20 million in cash, although the final price could reach $US100 million depending on progress in developing the acquired products, with provision for future royalty payments as well. The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years. These are substantially derisked, Mesoblast chief executive, Professor Silviu Itescu said of the two advanced products, an agent for treating some Crohns disease cases along with a treatment for some graft versus host disease cases resulting from stem cell transplants. Advertisement In afternoon trading, the shares were up 5.1 per cent at $5.76. Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells … Continue reading →

Shares in stem cells group Mesoblast have surged back to their highest level in two months on news it is to spend up to $100 million buying a suite of patents in the US which have the potential to deliver revenues sooner than expected. Earlier today, it disclosed details of the purchase of a clutch of assets from US-based Osiris Therapeutic for an initial $US20 million in cash, although the final price could reach $US100 million depending on progress in developing the acquired products, with provision for future royalty payments as well. The purchase brings with it two products already in their final stage of clinical trials with approvals for launch in Canada and New Zealand, and with the potential to win clearance for launch in the key US market within two years. These are substantially derisked, Mesoblast chief executive, Professor Silviu Itescu said of the two advanced products, an agent for treating some Crohns disease cases along with a treatment for some graft versus host disease cases resulting from stem cell transplants. Advertisement In afternoon trading, the shares were up 5.1 per cent at $5.76. Like Mesoblast, Osiris has been developing therapeutic products that use so-called mesenchymal stem cells … Continue reading →

SHENZHEN, China, Oct. 10, 2013 /PRNewswire/ -- GNT Biotech and Medicals Corporation announces the grant of an exclusive license from Shenzhen Chipscreen Biosciences Ltd.for the development and commercialization of Chidamide in Taiwan. Chidamide, an oral, selective histone deacetylase (HDAC) inhibitor, is currently being evaluated in Phase II trials by Chipscreen Biosciences in Peripheral T-Cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) and Non-Small Cell Lung Cancer patients (NSCLC). GNTbm will develop and commercialize Chidamide primarily in PTCL, NSCLC and will also retain the rights to develop and commercialize Chidamide in other oncology indications in Taiwan. About Chidamide Chidamide is a selective HDAC inhibitor against subtype 1, 2, 3 and 10, and being studied in multiple clinical trials as a single agent or in combination with chemotherapeutic agents for the treatment of various hematological and solid cancers. Its anticancer effects are thought to be mediated through epigenetic modulation via multiple mechanisms of action, including the inhibition of cell proliferation and induction of apoptosis in blood derived cells, inhibition of epithelial to mesenchymal transition (EMT, a process that is highly relevant to tumor cell metastasis and drug resistance), induction of tumor specific antigen and antigen-specific T cell cytotoxicity, enhancement of NK cell anti-tumor … Continue reading →

Public release date: 9-Oct-2013 [ | E-mail | Share ] Contact: Sally Garneski pressinquiry@facs.org 312-202-5409 American College of Surgeons WASHINGTON, DCResearchers at the University of Michigan Department of Surgery have begun testing an alternative to embryonic stem cells that could one day regenerate muscle tissue for babies with congenital heart defects. A research-in-progress report on this new approach, which uses amniotic stem cells, was presented today at the 2013 Clinical Congress of the American College of Surgeons. Although this research is still in an early phase, this new approach has the potential to one day help thousands of babies born each year with congenital heart defects. Typically, a pregnant woman can have a fetal ultrasound performed to find out the sex of her baby between 18 and 20 weeks gestation. But each year during pregnancy or after birth, 40,000 women also find out that their babies have birth defects in their hearts, according to the Centers for Disease Control and Prevention.* Babies with congenital heart defects often go through multiple heart operations or even a transplant before their first birthday. But Shaun Kunisaki, MD, a pediatric surgeon and assistant professor of surgery at the University of Michigan, and his surgical … Continue reading →

Purtier Placenta Live stem Cell Therapy Miracle - Mr Wilson Grandma is healthy now after 8 months This video is from YouTube Channel-wilsonho ho. In his YouTube Wilson never mentions much. Just a short message, My grandmother is healthy now after 8months ... By: Purtier Placenta Singapore Original … Continue reading →

Synovial stem cells and cartilage for osteoarthritis http://www.stemcellsarthritistreatment.com Lee and colleagues reported in the journal arthroscopy their results using mesenchymal stem cells obtained from th... By: Nathan Wei … Continue reading →

Stem Cell Therapy Treatment for Spinal Cord Injury c6 c7 by Dr Alok Sharma, Mumbai, India Improvement seen after Stem Cell Therapy Treatment for Spinal Cord Injury c6-c7 by Dr Alok Sharma, Mumbai, India. After Stem Cell Therapy 1. Standing toleran... By: Neurogen Brain and Spine Institute … Continue reading →

What are the important issues when it comes to cartilage repair and stem cells? http://www.stemcellsarthritistreatment.com What are the important issues when it comes to cartilage repair? The first is to know that whatever method is used... By: Nathan Wei … Continue reading →

Oct. 2, 2013 The research group led by Professor Takashi Tsuji of Tokyo University of Science and Organ Technologies Inc. has provided a proof-of-concept for bioengineered mature organ replacement as a regenerative therapy. Current advances in regenerative therapies have been influenced by the study of embryonic development, stem cell biology, and tissue engineering technologies. The ultimate goal of regenerative therapy is to develop fully functional bioengineered tissues that can replace lost or damaged organs following disease, injury or aging. A research group led by Professor Takashi Tsuji (Professor in the Research Institute for Science and Technology, Tokyo University of Science, and Director of Organ Technologies Inc.) has provided a proof-of-concept for bioengineered mature organ replacement as a regenerative therapy. Dr. Tsuji's research group (M. Ogawa et al.) reports the fully functional regeneration of a salivary gland that reproduces the morphogenesis induced by reciprocal epithelial and mesenchymal interactions through the orthotopic transplantation of a bioengineered salivary gland germ as a regenerative organ replacement therapy. The bioengineered germ developed into a mature gland through acinar formations with the myoepithelium and innervation. The bioengineered submandibular gland produced saliva in response to the administration of pilocarpine and gustatory stimulation by citrate, protected against oral … Continue reading →